AbbVie Inc. (ABBV)
| Market Cap | 405.55B |
| Revenue (ttm) | 58.33B |
| Net Income (ttm) | 3.72B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.10 |
| PE Ratio | 109.31 |
| Forward PE | 19.58 |
| Dividend | $6.56 (2.86%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 7,149,387 |
| Open | 227.52 |
| Previous Close | 226.87 |
| Day's Range | 226.81 - 230.71 |
| 52-Week Range | 163.81 - 244.81 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 232.05 (+1.08%) |
| Earnings Date | Oct 31, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $232.05, which is an increase of 1.08% from the latest price.
News
AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition
AbbVie earns a Strong Buy rating in my book, driven by Rinvoq's label expansions and robust immunology pipeline growth. ABBV achieved FDA approval for Rinvoq in giant cell arteritis and reported stron...
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORT...
Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending
The Investment Committee give you their top stocks to watch for the second half.
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
- Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisa...
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-trea...
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette. The brand's new HA5® moisturizer is design...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total un...
AbbVie expects $2.7 billion R&D charge in third quarter
Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses.
AbbVie: Wins Accumulating While We Wait For Next BD Steps
AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guid...
ABBV Stock vs. Eli Lilly & Merck
AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer's agreement to lower its drug prices for Medicaid and a White House decision...
AbbVie to Host Third-Quarter 2025 Earnings Conference Call
NORTH CHICAGO, Ill. , Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens.
Natrelle® Awarded Supplier Agreement from Vizient
This agreement grants Vizient clients enhanced access to Natrelle®, the broadest selection of breast implant options on the market. IRVINE, Calif.
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to Ab...
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (...
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its mult...
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by ...
AbbVie to launch ovarian cancer drug in UK at the same list price as US
AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
The list price will be consistent with the United States to reflect the value of the innovation AbbVie is committed to ensuring that developed nations fully recognize the value of our medicines in imp...
AbbVie For Healthy Dividend Growth
AbbVie is rated a strong buy for its strong dividend growth, robust fundamentals, and proven track record as a Dividend King. ABBV offers a compelling mix of a 3% yield and nearly 7% annual historical...
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials rei...
AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. Spherix Global Insights finds...